A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Clinical trial NCT05377996 · RECRUITING

Trial details

NCT number: NCT05377996
Sponsor: Day One Biopharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer Breast Cancer Endometrial Cancer Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cavity Cancer Adenoid Cystic Carcinoma

Start date: 2022-08-15
Primary completion: 2027-02-01
Enrollment: 360

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.